- LoI between Mithra and Fuji, market leader in Japan, for Estetrol-based products in Women’s Health; multiple indications to be determined in common agreement
- Japanese clinical trials to be conducted and financed by Fuji
- Potential milestones in the double-digit million EUR range
Liège, Belgium 24 June 2016 – Mithra Pharmaceuticals is pleased to announce it has signed a Letter of Intent with Fuji Pharmaceuticals to work towards a broad partnership on Estetrol in women’s health, in multiple indications to be determined in common agreement. Both parties intend to finalize their partnership in an agreement before the end of this year. This important partnership (involving investments and potential milestones in the double-digit million range) between Mithra and Fuji Pharmaceuticals, the market leader in Women’s Health in Japan, validates Mithra’s strategy of seeking out the Women’s Health leaders in markets around the world.